Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alumis Inc. (ALMS : NSDQ)

• Company Description    Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 170

• Price / Volume Information    Yesterday's Closing Price: $9.76 Daily Weekly Monthly 20 Day Moving Average: 1,095,661 shares Shares Outstanding: 104.39 (millions) Market Capitalization: $1,018.88 (millions) Beta: -2.09 52 Week High: $12.44 52 Week Low: $2.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.59% 17.79% 12 Week 115.45% 111.98% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 280 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-231-6625 fax: - adil@crescendo-ir.com http://www.alumis.com

• General Corporate Information    Officers Martin Babler - Chief Executive Officer; President and Director John Schroer - Chief Financial Officer Srinivas Akkaraju - Director Alan B. Colowick - Director Patrick Machado - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 022307102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/18/26 Share - Related Items Shares Outstanding: 104.39 Most Recent Split Date: (:1) Beta: -2.09 Market Capitalization: $1,018.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.85 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/18/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.65 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 38.73% vs. Previous Quarter: 9.40% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -22.51% ROE 12/31/25 - - 09/30/25 - -121.25 06/30/25 - -119.15 ROA 12/31/25 - - 09/30/25 - -92.54 06/30/25 - -92.50 Current Ratio 12/31/25 - - 09/30/25 - 6.01 06/30/25 - 6.05 Quick Ratio 12/31/25 - - 09/30/25 - 6.01 06/30/25 - 6.05 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,146.94 06/30/25 - -1,177.16 Book Value 12/31/25 - - 09/30/25 - 3.69 06/30/25 - 4.66 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©